Catalog No.A2006 Synonyms: rhuMab VEGF Humanized and Non-humanized mouse model applicable
For research use only. Not for use in humans.
Bevacizumab (anti-VEGF) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.
Cited by 7 Publications
Choose Selective VEGFR Inhibitors
|Description||Bevacizumab (anti-VEGF) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.|
Gly88 in human VEGF is essential for binding bevacizumab and this residue also underlies the species specificity of bevacizumab binding, since a serine residue is found in mouse and rat VEGF at the corresponding position. In common with its mouse counterpart, bevacizumab binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments. It does not neutralize other members of the VEGF gene family, such as VEGF-B or VEGF-C.
|In vivo||The terminal half-life of bevacizumab in humans is 17-21 days. Bevacizumab inhibits the growth of human tumour cell lines in nude mice, achieving a maximal inhibition at the dose of 1-2 mg per kg twice weekly. Half-maximal inhibition requires 0.1-0.5 mg per kg doses. Safety evaluation studies of bevacizumab are conducted in Macaca fascicularis (cynomolgus monkey), a species in which bevacizumab is expected to be pharmacologically active, considering the complete identity between human and cynomolgus VEGF isoforms at the protein level. Following administration of bevacizumab for four or thirteen weeks, young adult cynomolgus monkeys exhibits a physeal dysplasia characterized by a dose-related increase in hypertrophied chondrocytes and inhibition of vascular invasion of the growth plate, which is very similar to the growth-plate lesion observed in mice treated with Flt(1-3)-IgG. Other expected effects of prolonged bevacizumab administration are suppression of angiogenesis in the female reproductive tract, resulting in decreased ovarian and uterine weights, and an absence of corpora lutea. Both the growth-plate and ovarian changes are reversible with cessation of treatment. Importantly, no other treatment-related effects are observed following bevacizumab administration at doses up to 50 mg per kg. After s.c. administration, rhuMAb VEGF has a bioavailability of 69% in rats and 100% in mice and cynomolgus monkeys. It binds to primate VEGF and with lower affinity to rabbit VEGF but not to rat or mouse VEGF.|
|Formulation||PBS buffer, pH 7.2|
|Storage||Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles|
If you have any other enquiries, please leave a message.
Frequently Asked Questions
How to store the antibody?
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.